This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Epilepsy is the third leading neurologic cause of premature death and disability worldwide, behind only stroke and dementia.1 During the 1990s, the Decade of the Brain, epilepsy also became one of the more treatable neurologic conditions. Eight new antiepileptic drugs (AED) were brought to market. The vagus nerve stimulator was introduced. High-resolution MRI permitted more cost-effective identification of appropriate surgical candidates, culminating in the first-ever randomized controlled trial comparing surgery to medical treatment.2 During the same period, there was increasing awareness of the need to include the patient’s perspective when assessing treatment effects, as reflected by the proliferation of self-report measures of treatment side effects and health-related quality of life (QOL).3
For the majority of persons with epilepsy, the goal of “no seizures, no side effects” is now within reach. But how widely and effectively are the new drugs, devices, and diagnostic tools being …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham